Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00126386
Status:
COMPLETED
Last Update Posted:
2011-11-21
First Post:
2005-08-02
Brief Title:
Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community
Sponsor:
Alberta Health services
Organization:
AHS Cancer Control Alberta
Study Overview
Official Title:
Zoledronic Acid Zometa for the Management of Tumor-induced Hypercalcemia TIH and Malignant Bone Pain MBP in the Community A Feasibility Study
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Treatment in the home and hospice of long-term care facilities particularly for non-ambulatory patients could provide significant advantages for patients and for the region The Calgary Health Region has a unique resource in the home parenteral therapy program HPTP With the assistance of HPTP patients requiring bisphosphonate treatment for the management of tumor-induced hypercalcemia TIH or malignant bone pain MBP could be treated in the community ie at home However the resources required and the costs associated with community-based homes hospices long-term care facilities treatment of TIH and MBP need to be identified and evaluated so as to guide future regional decision making
Detailed Description:
Treatment in the home and hospice of long-term care facilities particularly for non-ambulatory patients could provide significant advantages for patients and for the region The Calgary Health Region has a unique resource in the home parenteral therapy program HPTP With the assistance of HPTP patients requiring bisphosphonate treatment for the management of TIH or MBP could be treated in the community ie at home However the resources required and the costs associated with community-based homes hospices long-term care facilities treatment of TIH and MBP need to be identified and evaluated so as to guide future regional decision making
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 17280 | None | None | None |